ClinicalTrials.gg
RecruitingNCT05653622SIB-DOPAUpdated Feb 4, 2026

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma

A Phase 2 interventional study of Integrated boost technique (SIB) guided by PET FDOPA in Glioblastoma Multiforme, Adult, sponsored by Centre Paul Strauss. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Centre Paul Strauss · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.

Planned enrollment
71st of 131
75 · median 80
Started
2025
with 7 others
Phase 2
33 of 150
6 open now
Primary completion
2028-07
later than 35 of 50 live
Registered
119th of 150
by date

Among the 150 studies in Glioblastoma with a site in France, this one is the 71st largest by planned enrollment of the 131 interventional ones that give a count, is one of 8 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 35 of the 50 other live ones, and was the 119th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Glioblastoma with a site in France, or all of them as a file.
02

Study summary

Glioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall survival (OS) ranged from 15 to 18 months.

Some frail patients received hypofractionated radiation and concomitant and adjuvant TMZ. For some, the radiation dose is not optimal. Moreover, recurrences develop mainly in the initial tumor site. These two reasons justify increasing the dose. To limit the movements of these fragile patients, the method consists of increasing the dose without increasing the number of sessions by using the Simultaneous Integrated Boost (SIB) which increases the dose in targeted volumes while the rest of the volume receives a minimum dose. A phase I trial showed the possibility of increasing the dose in SIB up to 80 Gy in a part of the GBM enhanced on MRI.

FDOPA PET detects certain more aggressive tumor areas, areas likely to recur. Integrating them into the SIB seems appropriate. A phase II trial showed the interest of SIB guided by FDOPA PET in terms of progression-free survival but without impact on OS. This study differed from the one the investigators propose, because a dose and conventional fractionation, identical to that of the European Organization for Research and Treatment of Cancer/National Cancer Information Center (NCIC/EORTC) protocol were delivered, the gliomas were unmethylated MGMT, less likely to respond. Studies with SIB and hypofractionation are often retrospective and for others, hypofractionation was debatable and the dose increase was not based on PET capture but on MRI. However, a prospective phase II study, with SIB and hypofractionation, not integrating FDopa PET has demonstrated the relevance of SIB.

In this project, the investigators propose to use the integrated boost technique (SIB) guided by PET FDOPA to increase the radiation dose in GBM, in patients either fragile and partially operated, or only biopsied and for whom the prognosis is the most pejorative.

03

Conditions studied

  • Glioblastoma Multiforme, Adult

Browse trials for

Keywords

  • glioblastoma
  • intensity modulated radiation therapy
  • 18F-DOPA-PET imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unfit patient without indication to the STUPP protocol :

Cohort 1 : Non-operable patients and ≥ 18 years old or ≤ 70 years old and Index (KI) ≥ 50% on inclusion AND Result of a available Cohort 2 : Patients > 70 years old and Balducci score I or II and KI ≥ 60% on inclusion AND Partial resection (defined on the remnographic criteria of postoperative MRI) OR biopsy result available

  • proven glioblastoma
  • Increased metabolism of amino acids in PET FDOPA allowing contouring the Biological Target Volume (BTV)

Exclusion criteria

Exclusion Criteria:

  • Patients with an indication for irradiation according to the STUPP protocol (fit patient)
  • Patient with a to MRI or PET
  • Limit of the provisional target volume or Planning target volume (PTV), second PTV \< 2 cm from the chiasm and the optic nerves
  • Absence of uptake of FDopa
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    SIB-DOPA

    Procedure: Integrated boost technique (SIB) guided by PET FDOPA

Interventions

  • ProcedureIntegrated boost technique (SIB) guided by PET FDOPA

    intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Evaluate the overall survival (OS) of patients with glioblastoma treated with integrated boost (SIB) with increased dose guided by FDOPA PET

    Time frame: At 24 months after inclusion

Secondary outcomes

  1. Progression-Free Survival (PFS)

    To assess the progression-free survival (PFS) of patients with glioblastoma treated with SIB with increased dose guided by FDOPA PET

    Time frame: At 24 months after inclusion

  2. Sites of progression: distant, marginal or in-field progression

    The progression will be defined by its location by comparing the progression imaging with that used for dosimetry. It will be considered "distant" if it develops beyond the 95% isodose, "marginal" if it cuts the 95% isodose and "in-field" if it is completely within the 95% isodose. The 95% isodose is the reference isodose for the prescription of hypofractionated radiotherapy.

    Time frame: At the date of progression, assessed up to 24 months

  3. Assess the rate of acute complications of grade ≥ 3

    Acute toxicities are defined as toxicities by the Common Terminology Criteria for Adverse Events (CTCAE v5) occurring within 6 months of the start of radiotherapy.

    Time frame: At 6 months after the start of radiotherapy

  4. Characterize the PET parameters during progression

    PET Parameters: * Standardized Uptake Value (SUV) max tumor, SUV max tumor/healthy tissue, SUV max T/striatum * SUV mean tumor, SUV mean tumor/healthy tissue, SUV mean T/striatum

    Time frame: At the date of progression, assessed up to 24 months

  5. Evolution of the PET parameters

    PET Parameters: * Standardized Uptake Value (SUV) max tumor, SUV max tumor/healthy tissue, SUV max T/striatum * SUV mean tumor, SUV mean tumor/healthy tissue, SUV mean T/striatum

    Time frame: Change between baseline and the date of progression, assessed up to 24 months

  6. Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    The quality of life will be measured at the inclusion with Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At inclusion

  7. Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    The quality of life will be measured at the inclusion with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At inclusion

  8. Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    The quality of life will be measured at 3 months with Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 3 months after inclusion

  9. Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    The quality of life will be measured at 3 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 3 months after inclusion

  10. Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    The quality of life will be measured at 6 months with Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 6 months after inclusion

  11. Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    The quality of life will be measured at 6 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 6 months after inclusion

  12. Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    The quality of life will be measured at 12 months with Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 12 months after inclusion

  13. Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    The quality of life will be measured at 12 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 12 months after inclusion

  14. Assess quality of life measured with Quality of Life Questionnaire-Cancer 30items (QLQ-C30)

    The quality of life will be measured at 18 months with Quality of Life Questionnaire-C30 (Cancer 30items). All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 18 months after inclusion

  15. Assess quality of life measured with Quality of Life Questionnaire-Brain Neoplasms 20items (QLQ-BN20)

    The quality of life will be measured at 18 months with Quality of Life Questionnaire - BN20 (Brain Neoplasms 20items). All items are scored 1 (worse outcome) to 4 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: At 18 months after inclusion

  16. Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and Overall survival

    MGMT promoter methylation status (binary variable, determined by either Polymerase Chain reaction (PCR) or immunohistochemistry)

    Time frame: At 24 months after inclusion

  17. Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and Progression-Free Survival

    MGMT promoter methylation status (binary variable, determined by either PCR or immunohistochemistry)

    Time frame: At 24 months after inclusion

  18. Correlate O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status and acute toxicities

    MGMT promoter methylation status (binary variable, determined by either PCR or immunohistochemistry)

    Time frame: At 24 months after inclusion

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977. PubMed 28296618 ↗
  • Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F, Blanchard N, Lagneau E, Maingon P, Noel G. A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer Radiother. 2016 May;20(3):193-8. doi: 10.1016/j.canrad.2015.12.005. Epub 2016 Apr 23. PubMed 27117900 ↗
  • Somme F, Bender L, Namer IJ, Noel G, Bund C. Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. Cancer Imaging. 2020 Oct 6;20(1):70. doi: 10.1186/s40644-020-00348-5. PubMed 33023662 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 36 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 16, 2022
StartActual
Jun 23, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653622
Lead sponsor
Centre Paul Strauss
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Jun 23, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Feb 4, 2026

Study contacts

Anne ANTHONY
Contact
promotion-rc@institut-strauss.fr
+33(0)388252413
MANON VOEGELIN
Contact
promotion-rc@institut-strauss.fr
+33(0)3 68 33 95 23
Caroline BUND
principal investigator · Centre Paul Strauss

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion